- Home
- AUTL vs ALLO Comparison
AUTL vs ALLO Comparison
Compare AUTL & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUTL | ALLO |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.2M | 483.7M |
| IPO Year | 2025 | 2018 |
Fundamental Metrics
Financial Performance| Metric | AUTL | ALLO |
|---|---|---|
| Price | $1.60 | $1.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $8.73 | ★ $9.00 |
| AVG Volume (30 Days) | 1.5M | ★ 5.6M |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,120,000.00 | N/A |
| Revenue This Year | $98.68 | N/A |
| Revenue Next Year | $28.47 | $255.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 496.00 | N/A |
| 52 Week Low | $1.18 | $1.04 |
| 52 Week High | $2.58 | $4.46 |
Technical Indicators
Market Signals| Indicator | AUTL | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 35.87 | 26.53 |
| Support Level | $1.37 | N/A |
| Resistance Level | $1.73 | $2.22 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 6.41 | 18.82 |
Price Performance
Historical ComparisonAbout AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).